+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chlamydia Infections - Pipeline Review, H2 2020

  • ID: 5174813
  • Drug Pipelines
  • September 2020
  • Region: Global
  • 88 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Abera Bioscience AB
  • BlueWillow Biologics Inc
  • Eurocine Vaccines AB
  • Genetic Immunity Inc
  • Microbiotix Inc
  • QureTech Bio AB
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2020, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abera Bioscience AB
  • BlueWillow Biologics Inc
  • Eurocine Vaccines AB
  • Genetic Immunity Inc
  • Microbiotix Inc
  • QureTech Bio AB
  • MORE
Introduction
  • Report Coverage
Chlamydia Infections - Overview

Chlamydia Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Chlamydia Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Chlamydia Infections - Companies Involved in Therapeutics Development
  • Abera Bioscience AB
  • Abivax SA
  • BlueWillow Biologics Inc
  • Erganeo
  • Eurocine Vaccines AB
  • Evofem Biosciences Inc
  • Genetic Immunity Inc
  • Lawrence Livermore National Laboratory
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • Microbiotix Inc
  • Prokarium Ltd
  • QureTech Bio AB
  • Traccine Pharmaceuticals
  • Vault Pharma Inc
  • Vaxine Pty Ltd
  • Yaso Therapeutics Inc
Chlamydia Infections - Drug Profiles

(citric acid + lactic acid + potassium bitartrate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Ab-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ABX-196 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ChlamyDerm - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia trachomatis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PEG-2S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Peptide to Inhibit CPAF for Chlamydia Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PPCM - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule for Chlamydia Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
solithromycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
VPI-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chlamydia Infections - Dormant Projects

Chlamydia Infections - Product Development Milestones
  • Featured News & Press Releases
  • May 12, 2020: Eurocine Vaccines receives notification of grant to prepare for the manufacture of the chlamydia vaccine candidate
  • May 07, 2020: Eurocine Vaccines presents end results from preclinical study with chlamydia vaccine
  • Jan 27, 2020: Eurocine Vaccines launches new preclinical study with chlamydia vaccine candidate
  • Aug 13, 2019: Progress made in developing first Chlamydia vaccine
  • Mar 13, 2019: Yaso Therapeutics awarded $2 million SBIR grant from the National Institutes of Health to complete preclinical studies of a new female contraceptive that prevents disease transmission
  • Sep 26, 2018: BlueWillow Biologics awarded grant for chlamydia vaccine development
  • Apr 20, 2017: New weapon in fight against antibiotic resistance discovered
  • Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
  • Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
  • Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
  • Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
  • Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Chlamydia Infections, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2020
  • Chlamydia Infections - Pipeline by Abivax SA, H2 2020
  • Chlamydia Infections - Pipeline by BlueWillow Biologics Inc, H2 2020
  • Chlamydia Infections - Pipeline by Erganeo, H2 2020
  • Chlamydia Infections - Pipeline by Eurocine Vaccines AB, H2 2020
  • Chlamydia Infections - Pipeline by Evofem Biosciences Inc, H2 2020
  • Chlamydia Infections - Pipeline by Genetic Immunity Inc, H2 2020
  • Chlamydia Infections - Pipeline by Lawrence Livermore National Laboratory, H2 2020
  • Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H2 2020
  • Chlamydia Infections - Pipeline by Merck & Co Inc, H2 2020
  • Chlamydia Infections - Pipeline by Microbiotix Inc, H2 2020
  • Chlamydia Infections - Pipeline by Prokarium Ltd, H2 2020
  • Chlamydia Infections - Pipeline by QureTech Bio AB, H2 2020
  • Chlamydia Infections - Pipeline by Traccine Pharmaceuticals, H2 2020
  • Chlamydia Infections - Pipeline by Vault Pharma Inc, H2 2020
  • Chlamydia Infections - Pipeline by Vaxine Pty Ltd, H2 2020
  • Chlamydia Infections - Pipeline by Yaso Therapeutics Inc, H2 2020
  • Chlamydia Infections - Dormant Projects, H2 2020
List of Figures
  • Number of Products under Development for Chlamydia Infections, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Abera Bioscience AB
  • Abivax SA
  • BlueWillow Biologics Inc
  • Erganeo
  • Eurocine Vaccines AB
  • Evofem Biosciences Inc
  • Genetic Immunity Inc
  • Lawrence Livermore National Laboratory
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • Microbiotix Inc
  • Prokarium Ltd
  • QureTech Bio AB
  • Traccine Pharmaceuticals
  • Vault Pharma Inc
  • Vaxine Pty Ltd
  • Yaso Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll